Poster: MM-155: Phase 3 MAIA Study: Overall Survival (OS) Results with Daratumumab, Lenalidomide, and Dexamethasone (D-Rd) vs Lenalidomide and Dexamethasone (Rd) in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma (TIE-NDMM)
Year: 2021
Type: article
Authors: Robert Orlowski, Thierry Facon, Shaji Kumar, Torben Plesner, Philippe Moreau, Nizar Bahlis, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O’Dwyer, Aurore Perrot, Christopher Venner, Katja Weisel, Joseph Mace, Noopur Raje, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Tahamtan Ahmadi, Jianping Wang, Rian Van Rampelbergh, Clarissa Uhlar, Brenda Tromp, Maria Delioukina, Jessica Vermeulen, Saad Usmani
Institutions: The University of Texas MD Anderson Cancer Center, Université de Lille, Centre Hospitalier Universitaire de Lille, Mayo Clinic, University of Southern Denmark, Vejle Sygehus, Nantes Université, University of Calgary, University of Wolverhampton, The Royal Wolverhampton NHS Trust, Karolinska University Hospital, Karolinska Institutet, Hôpital Cardiologique du Haut-Lévêque, The University of Melbourne, St Vincent's Hospital Melbourne, University Hospital Heidelberg, National Center for Tumor Diseases, Ollscoil na Gaillimhe – University of Galway, Université Toulouse III - Paul Sabatier, Centre Hospitalier Universitaire de Toulouse, Institut universitaire du cancer de Toulouse Oncopole, Université de Toulouse, University of Alberta, Cross Cancer Institute, University Medical Center Hamburg-Eppendorf, Massachusetts General Hospital, Centre Hospitalier Départemental Vendée, Centre Hospitalier Universitaire de Caen Normandie, Hôpital Necker-Enfants Malades, Centre Hospitalier Universitaire de Poitiers, Genmab (United States), Janssen Research & Development (United States), Janssen (Belgium), Janssen (Netherlands), Levine Cancer Institute
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4200325876